Dr. Saroj Verma
Associate Professor – Medical & Allied Sciences
In silico exploration of anti-infective molecules (Virtual screening/QSAR), investigation of mechanistic aspects of molecules (Molecular docking/ dynamics simulation), studies on drug target mutations with the help of protein informatics, synthesis, and biological screening of designed molecules.
- Ph.D (Jan-2011- Oct-2016)
- M.Pharm.(July-2007-Aug-2009)
- B.Pharm. (July-2003-July-2007)
12 Years
- Made original contributions to drug discovery and bioinformatics through several publications, including identification methods for target similarity searches and applications of protein/mutation informatics for determining how mutations affect drug targets.
- 2022: Verma S*, Patil VM, Gupta MK. Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. Drug Discov Today. 2022 Jul 3:103312. Mentioned in more than 8 national/international news.
- 2021: Received first prize in oral presentation in International Conference on Advances in Pharmaceutical and Health Sciences (APHS-2021) dated on 07th and 08th, October 2021, Organized by KIET school of Pharmacy in association with CSIR-Indian institute of toxicological research Lucknow, India.
- 2020: Invited as resource person to deliver lecture in international workshop and summer school.
- 2013: Awarded Senior Research Fellowship in professional Science (SRF-P) by the Department of Science & Technology (DST), New Delhi, India under Innovation in Science Pursuit for Inspired Research (INSPIRE) scheme.
- 2011: Awarded Junior Research Fellowship in professional Science (JRF-P) by the Department of Science & Technology (DST), New Delhi, India under Innovation in Science Pursuit for Inspired Research (INSPIRE) scheme.
- 2010: Ranbaxy Gold Medal” for M. Pharm.-2009 examination topper from Devi Ahilya University.
- 2007: Awarded GATE-Scholarship by the Ministry of Human Resource Development (MHRD).
- Bioinformatics and Drug Discovery Society [BIDDS] Life Membership.
- ACS Membership.
- Lifetime member of Bioinformatics and Drug Discovery Society (BIDDS).
- Reviewer: ACS Omega, Journal of Biomolecular Structure and Dynamics and Current Topics in Medicinal Chemistry
Book Chapter
- Verma, S*.; Tonk, R. K. (2020) Rhomboid Proteases Leading to Cancer: Structures, Functions and Inhibition, In Gupta S.P. (Ed.), Cancer Leading Proteases. Acedemic press (Elsevier), London (UK)/San Diego (US). pp, 327-357.
Review Article
- Verma S, Prabhakar Y. S. Target based drug design – a reality in virtual sphere. Curr Med Chem. 2015, 22, 1603-30. (Impact factor: 4.740).
- Patil VM, Masand N, Verma S, Masand V. Chromones: Privileged scaffold in anticancer drug discovery. Chem Biol Drug Des. 2021 Sep 13. Epub ahead of print. PMID: 34519163. (Impact factor: 2.873).
- Utsab Debnath, Saroj Verma*, Jeevan Patra, Sudip Kumar Mandal, A review on recent synthetic routes and computational approaches for antibody drug conjugation developments used in anti-cancer therapy, Journal of Molecular Structure, 2022, 1256, , 132524, ISSN 0022-2860 (Impact factor: 3.841).
- Vaishali M. Patil, Saroj Verma, Neeraj Masand. Prospective mode of action of Ivermectin: SARS-CoV-2. European Journal of Medicinal Chemistry Reports, 2022, 4, 100018.
- Saroj Verma*, Vaishali M. Patil, Manish K. Gupta. Mutation Informatics: SARS-Cov2 Receptor Binding Domain of Spike Protein. accepted in Drug Discovery Today (Impact factor 8.369).
- Saroj Verma, Neeraj Masand, Rameshwar S. Cheke, Vaishali M. Patil. Protein informatics and vaccine development: Cancer case study (Under consideration, revision submitted: Current Topics in Medicinal Chemistry, Impact factor: 3.57).
Research Publications
- Dewaker V, Srivastava PN, Verma S, Srivastava AK, Prabhakar YS. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. J Biomol Struct Dyn. 2021 Oct 18:1-24. (Impact factor: 5.235).
- Dewaker, V.; Srivastava, P.N.; Verma, S.; Prabhakar, Y.S. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds. J. Biomol. Struct. Dyn., 2019, 1-17. (Impact factor: 5.235).
- Kamil, R. F.; Debnath, U.; Verma, S.; Prabhakar, Y.S. Identification of adjacent NNRTI binding pocket in multi-mutated HIV1-RT Enzyme Model: An in-silico study. Curr. HIV Res., 2018, 16, 121-129 (Impact factor: 1.580).
- Verma, S.; Pandey, S.; Agarwal, P.; Verma, P.; Deshpande, S.; Saxena, J.K.; Srivastava, K.; Chauhan, P.M.S.; Prabhakar, Y. S. N-(7-chloroquinolinyl-4-aminoalkyl) arylsulfonamides as antimalarial agents: Rationale for the activity with reference to inhibition of hemozoin formation. RSC Advances, 2016, 6, 25584–25593. (Impact factor: 3.36).
- Verma S, Debnath U, Agarwal P, Srivastava K, Prabhakar Y. S. In Silico Exploration for New Antimalarials: Arylsulfonyloxy Acetimidamides as Prospective Agents. J. Chem. Inf Model, 2015, 55, 1708-1719 (Impact factor: 6.162).
- Debnath U, Verma S, Singh P, Rawat K, Gupta S. K, Tripathi R. K, Siddiqui H. H, Katti S. B, Prabhakar Y. S. Synthesis, Biological Evaluation and Molecular Modeling Studies of New 2,3-Diheteroaryl Thiazolidin-4-Ones as NNRTIs. Chem Biol. Drug Des., 2015, 86, 1285-1291. (Impact factor: 2.873).
- Sharma S, Saquib M, Verma S, Mishra N. N., Shukla P. K., Srivastava R, Prabhakar Y. S., Shaw A. K. Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents. Eur. J. Med. Chem., 2014, 83C, 474-489. (Impact factor: 7.088).
- Sharma B. K, Verma S, Prabhakar Y. S. Topological and physicochemical characteristics of 1,2,3,4-Tetrahydroacridin- 9(10H)-ones and their antimalarial profiles: a composite insight to the structure-activity relation. Curr. Comput. Aided Drug Des., 2013, 9, 317-35. (Impact factor: 1.639).
- Debnath U, Verma S, Jain S, Katti S. B., Prabhakar Y. S. Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics. J. Comput. Aided Mol. Des., 2013, 27, 637-654. (Impact factor: 4.179).
